Recombinant Human Anti-CD28 x Anti-EPCAM Bispecific Antibody (IgG-scFv) (IGFV-H233)

Recombinant Anti-CD28 x Anti-EPCAM Bispecific Antibody (IgG-scFv) is designed to be expressed as a LC and an extended HC with scFv moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Melanoma; Glioblastoma multiforme (GBM); Non-small cell lung (NSCLC); Colorectal cancer (CRC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & EPCAM

Type

IgG-scFv

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Melanoma Glioblastoma multiforme (GBM); Non-small cell lung (NSCLC); Colorectal cancer (CRC)Solid tumors

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

EPCAM

Gene ID

4072

UniProt ID

P16422

Alternative Names

EPCAM; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1; epithelial glycoprotein 314; human epithelial glycoprotein-2; cell surface glycoprotein Trop-1; adenocarcinoma-associated antigen; tumor-associated calcium signal transducer 1; major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD28 x Anti-EPCAM Bispecific Antibody (IgG-scFv) (IGFV-H233). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD28 x Anti-EPCAM Bispecific Antibody (IgG-scFv) (CAT#: IGFV-H233)

Specifications

Targets

Customer Reviews and Q&As